Invention Grant
- Patent Title: N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
-
Application No.: US16576997Application Date: 2019-09-20
-
Publication No.: US10975065B2Publication Date: 2021-04-13
- Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Mark Edward Schnute , Daniel Wei-Shung Kung , Daniel Copley Schmitt , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent John A. Wichtowski
- Main IPC: C07D413/14
- IPC: C07D413/14 ; A61P29/00 ; C07D401/12 ; C07D401/14 ; C07D405/14 ; C07D413/12 ; C07D417/12 ; C07D417/14 ; C07F9/6558
Abstract:
The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
Public/Granted literature
- US20200095239A1 N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS Public/Granted day:2020-03-26
Information query
